Loading stock data…
COLL
$34.40+1.13 (+3.40%)
After Hours$34.40+0.00 (+0.00%)· Last close Jun 9
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Collegium Pharmaceutical, Inc. in the Healthcare sector is trading at $34.40. Wall Street consensus targets $54.33 (6 analysts), implying a +57.9% move over the next 12 months. The stock is currently 32% below its 52-week high of $50.79, remaining 12.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +57.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$34.40
Potential Downside
0%
Whystock Fair Value$34.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.99%
Volume
Today's trading volume
248,042
Recent News
2 Reasons to Sell COLL and 1 Stock to Buy Instead
Shareholders of Collegium Pharmaceutical would probably like to forget the past six months even happened. The stock dropped 36.3% and now trades at $30.47. This might have investors contemplating their next move.
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has drawn investor attention after recent share price pressure, with the stock down 5% over the past day and 7% over the past week, extending weakness seen over the past month. See our latest analysis for Collegium Pharmaceutical. At the current share price of $31.78, Collegium Pharmaceutical’s recent slide, with the share price return down 20.53% over 90 days and 30.20% year to date, contrasts with its 8.43% one year total shareholder return and 50.90% three...
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio
Collegium Pharmaceutical Inc (NASDAQ:COLL) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to gain 57% over the next 12 months. On May 7, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q1 2026 results that both increased from the prior year and exceeded the […]
3 Growth Stocks We’re Skeptical Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Collegium Pharmaceutical’s first quarter was marked by solid execution and positive market reaction, supported by robust growth in its ADHD and pain management portfolios. Management attributed the quarter’s performance to significant prescription growth for JORNAY PM, improved prescriber adoption, and steady cash flow from its pain medicines, Belbuca and Xtampza ER. CEO Vikram Karnani highlighted, “JORNAY prescriptions grew by 14% year-over-year and generated $38.9 million in net revenue, up 36